Jeff Trost is the managing partner of the Laerdal Million Lives Fund, investing in global health technologies that contribute directly to saving lives. He is also the founding managing director of Greenbox Venture Partners, an early-stage healthcare technology venture capital fund, and is currently working with Rock Health's venture fund. Previously, Jeff was the Director of healthcare investment banking at GCA Savvian, where he spent nearly 12 years working with clients across a number of healthcare industries, including diagnostic and therapeutic imaging modalities, connected and remote patient monitoring devices, surgical equipment, digital health solutions and orthopedic / biologic products. In these healthcare sub-sectors, he has worked with and advised venture-backed, private equity and multi-national public companies on fundraising, M&A, joint ventures, partnering and other strategic transactions. In particular, Jeff has significant experience with cross-border M&A transactions between Japan / Asia Pacific and the US, having advised many Asian buyers on their investment and acquisition strategies in the US.Select transactions include: Santen Pharmaceutical's acquisition of InnFocus (Japan / US M&A)Signostic's capital raise / partnership with KKRPathfinder Technologies acquired by Analogic CorporationBioServe acquired by ReproCell (Japan / US M&A)Medicine360 licensing agreement with ActavisNihon Kohden's acquisition of Defibtech (Japan / US M&A)SonoSite acquired by FujiFilm (Japan / US M&A)Olympus' acquisition of Stryker's OP-1 biologic / bone assets (Japan / US M&A)SonoSite's acquisitions of VisualSonics and CardioDynamicsPrior to joining GCA Savvian, Jeff was a technology consultant with Accenture in their telecommunications group. Jeff received a BS in Biomedical Engineering, Electrical Engineering and Economics from Duke University.